menu
~
~
|
Common gene version optimizes thinking -- but with a possible downside
EurekAlert
press release - NIH/National Institute of Mental Health
Most people inherit a version of a gene that optimizes their brain's
thinking circuitry, yet also appears to increase risk for
schizophrenia, a severe mental illness marked by impaired thinking,
scientists at the National Institutes of Health's (NIH) National
Institute of Mental Health (NIMH) have discovered.
The
seeming paradox emerged from the first study to explore the effects of
variation in the human gene for a brain master switch, DARPP-32.
The researchers identified a common version of the gene and showed how
it impacts the way two key brain regions exchange information,
affecting a range of functions from general intelligence to attention.
Three fourths of subjects studied had at least one copy of the version
that results in more efficient filtering of information processed by
the brain's executive hub, the prefrontal cortex.
However,
the same version was also more prevalent among people who developed
schizophrenia, a severe mental illness marked by delusions,
hallucinations and impaired emotion that affects one percent of the
population.
"We have found that DARPP-32 shapes and controls a circuit coursing
between the human striatum and prefrontal cortex that affects key brain
functions implicated in schizophrenia, such as motivation, working
memory and reward related learning," explained Andreas
Meyer-Lindenberg, M.D.
"Our results raise the question of whether a gene variant favored by
evolution, that would normally confer advantage, may translate into a
disadvantage if the prefrontal cortex is impaired, as in
schizophrenia," added Daniel Weinberger, M.D.
"Normally,
enhanced cortex connectivity with the striatum would provide increased
flexibility, working memory capacity and executive control. But if
other genes and environmental events conspire to render the cortex
incapable of handling such information, it could backfire -- resulting
in the neural equivalent of a superhighway to a dead-end."
Meyer-Lindenberg, Weinberger and colleagues in the NIMH Genes,
Cognition and Psychosis program report their results in the February 9,
2007 issue of the Journal of Clinical Investigation.
Previous studies in animals over two decades, most notably by Nobel
Laureate and NIMH grantee Paul Greengard, M.D., Rockefeller University,
had established that DARPP-32 in the striatum switches streams of
information from multiple brain chemical systems for processing by the
cortex.
Both
the neurotransmitter that it works through, dopamine, and the
chromosomal site of its gene have been implicated in schizophrenia.
"Although several groups have looked for possible clinical relevance of
DARPP-32, they have not met with great success," noted Greengard. "This
study shows a strong connection between this molecule and human
cognition -- and perhaps with schizophrenia."
"These first glimpses of DARPP-32 at work in the living human brain
build on a quarter century of investigations by Greengard's team that
ultimately linked this pivotal protein to depression and substance
abuse as well as to schizophrenia," added NIMH Director Thomas Insel,
M.D.
To understand DARPP-32's role in the human brain, the NIMH researchers
used genetic, structural and functional magnetic resonance imaging, and
post-mortem techniques to identify the human gene's variants and their
functional consequences.
Seventy
five percent of subjects had the most
common version of the gene, which boosted circuit activation,
structural and functional connectivity and performance on thinking
tasks, likely by increasing gene expression.
In 257
affected families,
people with schizophrenia were more likely to have this common version
of the DARPP-32 gene.
###
Also participating in the study were: Richard Straub, Barbara Lipska,
Beth Verschinski, Terry Goldberg, Joseph Callicott, Michael Egan,
Stephen Huffaker, Venkata Mattay, Bhaskar Kolachana, Joel Kleinman,
NIMH.
Meyer-Lindenberg A, Straub R, Lipska B, Verchinski, B Goldberg T,
Callicott J, Egan M, Huffaker S, Mattay V, Kolachana B, Kleinman J,
Weinberger D. Genetic evidence implicating DARPP-32 in human
fronto-striatal structure, function and cognition. J.clin.investigation…
The National Institute of Mental Health (NIMH) mission is to reduce the
burden of mental and behavioral disorders through research on mind,
brain, and behavior.
More
information is available at the NIMH website
(www.nimh.nih.gov). The National Institutes of Health (NIH) -- The
Nation's Medical Research Agency -- includes 27 Institutes and Centers
and is a component of the U.S. Department of Health and Human Services.
It is the primary federal agency for conducting and supporting basic,
clinical and translational medical research, and it investigates the
causes, treatments, and cures for both common and rare diseases. For
more information about NIH and its programs, visit www.nih.gov
Source: EurekAlert
February 8, 2007
- - - -
More Neuroscience
articles
~ ~ ~
Related
Talent Development
Resources pages :
High Ability
Highly
Sensitive
Gifted
/ talented news
& resources
Articles:
high ability -
gifted/talented
More
giftedness articles
Giftedness
books
HSP
& gifted
books
Intensity
/
sensitivity
Intensity
/
sensitivity resources :
articles sites books
Introversion
/
shyness.
Introversion
resources : articles sites books
Perfectionism
Depression
and Creativity
Self-tests
: giftedness
~ ~ ~
|





Misdiagnosis
And Dual Diagnoses Of Gifted Children And Adults
|